Beam Therapeutics (BEAM) Proxy filing summary

Executive summary

• The annual meeting will be held virtually on June 3, 2026, to elect three Class III directors, ratify the appointment of Deloitte & Touche LLP as auditor, and approve executive compensation on an advisory basis.

• Shareholders can vote online, by phone, mail, or during the virtual meeting using a 16-digit control number.

• Proxy materials and the 2025 Annual Report are available online, supporting sustainability and cost reduction.

Voting matters and shareholder proposals

• Proposals include electing John Evans, John Maraganore, Ph.D., and Christi Shaw as Class III directors for three-year terms.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote to approve named executive officer (NEO) compensation.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of seven members, divided into three classes with staggered three-year terms.

• Six of seven directors are independent; John Evans, CEO, is not independent.

• Board committees include audit, compensation, nominating and corporate governance, and science and technology, all chaired by independent directors.

• Board emphasizes diversity and has a lead independent director structure.